Literature DB >> 18805553

Autoimmune-mediated oxidative stress and endothelial dysfunction: implications of accelerated vascular injury in type I diabetes.

Michael A Zimmerman1, Sonia C Flores.   

Abstract

The pathogenesis of cardiovascular disease in the setting of type 1 diabetes is not well-defined. The hypothesis that hyperglycemia is largely responsible for vascular endothelial dysfunction, and ultimately atherosclerosis, continues to evolve. However, despite tight glucose control, a subset of patients still develop clinically significant occlusive disease. While the specific mechanisms of persistent vascular injury are not clear, an increasing body of evidence suggests a dysregulated autoimmune response may contribute to the development of vascular injury. That is, the same inflammatory response that is responsible for pancreatic beta-cell destruction may facilitate chronic vascular endothelial injury prior to the onset of hyperglycemia. Herein, we discuss (1) the clinical experience with tight glycemic control and the risk of cardiovascular disease in patients with type 1 diabetes; (2) the cellular mechanisms involved in vascular endothelial injury; and (3) the long-term clinical implications of autoimmune-mediated vascular disease and current treatment strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18805553     DOI: 10.1016/j.jss.2008.04.026

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  When are type 1 diabetic patients at risk for cardiovascular disease?

Authors:  Trevor J Orchard; Tina Costacou
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

2.  Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice.

Authors:  Nada Sallam; Anat Fisher; Saeid Golbidi; Ismail Laher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-04       Impact factor: 3.000

3.  Autoimmune-mediated vascular injury occurs prior to sustained hyperglycemia in a murine model of type I diabetes mellitus.

Authors:  Michael A Zimmerman; Kathryn Haskins; Brenda Bradley; Jessica Gilman; Fabia Gamboni-Robertson; Sonia C Flores
Journal:  J Surg Res       Date:  2011-02-26       Impact factor: 2.192

4.  Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes.

Authors:  Joseph Pidala; Jongphil Kim; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Teresa Field; Janelle Perkins; Lia Perez; Hugo Fernandez; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-15       Impact factor: 5.742

5.  Evaluation of Oxidative Status in Elderly Patients with Multiple Cerebral Infarctions and Multiple Chronic Total Coronary Occlusions.

Authors:  Xia Li; Dianxuan Guo; Youdong Hu; Ying Chen
Journal:  Dis Markers       Date:  2022-06-28       Impact factor: 3.464

6.  Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Authors:  K C Herold; S E Gitelman; S M Willi; P A Gottlieb; F Waldron-Lynch; L Devine; J Sherr; S M Rosenthal; S Adi; M Y Jalaludin; A W Michels; J Dziura; J A Bluestone
Journal:  Diabetologia       Date:  2012-10-21       Impact factor: 10.122

7.  Garlic increases antioxidant levels in diabetic and hypertensive rats determined by a modified peroxidase method.

Authors:  Hana Drobiova; Martha Thomson; Khaled Al-Qattan; Riitta Peltonen-Shalaby; Zainab Al-Amin; Muslim Ali
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-20       Impact factor: 2.629

8.  Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+CD25+CD127- T-cells in children with long-lasting type 1 diabetes.

Authors:  Marcin Moniuszko; Barbara Glowinska-Olszewska; Malgorzata Rusak; Marta Jeznach; Kamil Grubczak; Danuta Lipinska; Robert Milewski; Anna Justyna Milewska; Milena Dabrowska; Ewa Jablonska; Adam Kretowski; Maria Gorska; Anna Bodzenta-Lukaszyk; Artur Bossowski
Journal:  Clin Dev Immunol       Date:  2013-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.